Cardio Diagnostics Holdings, Inc. Files S-1

TL;DR

CDIO filed an S-1, check it out.

AI Summary

Cardio Diagnostics Holdings, Inc. filed an S-1 form on November 22, 2024, detailing its business operations and financial status. The company, formerly known as Mana Capital Acquisition Corp. until June 29, 2021, is involved in in vitro & in vivo diagnostic substances. Its principal executive offices are located in Chicago, Illinois.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Cardio Diagnostics' business, financial health, and future plans, impacting potential investment decisions.

Risk Assessment

Risk Level: medium — As an S-1 filing, it represents a company seeking to go public or raise capital, which inherently carries risks associated with market conditions and business execution.

Key Numbers

• 333-283419 — SEC File Number (Identifies the specific SEC registration statement)
• 0001870144 — Central Index Key (Unique identifier for the company in SEC filings)

Key Players & Entities

• Cardio Diagnostics Holdings, Inc. (company) — Filer of the S-1
• Mana Capital Acquisition Corp. (company) — Former name of Cardio Diagnostics Holdings, Inc.
• 20210629 (date) — Date of name change
• 20241122 (date) — Filing date of the S-1
• Chicago, Illinois (location) — Business address of the company

FAQ

Key Financial Figures

• $0.00001 — te of 1,235,939 shares of common stock, $0.00001 par value (the "common stock" or the "s
• $1 — ebruary 2, 2030 at an exercise price of $1.78, subject to adjustment for stock spl
• $1.78 — a private placement at a sale price of $1.78 per unit (the "private placement"). We
• $0.2442 — e closing price of our common stock was $0.2442 and the closing price of our public war
• $0.0276 — losing price of our public warrants was $0.0276. You should carefully read this prospe
• $950 — gence platform. The Company earned only $950 and $17,065 in revenue for the years en
• $17,065 — tform. The Company earned only $950 and $17,065 in revenue for the years ended December
• $11,755 — er 31, 2022 and 2023, respectively, and $11,755 and $30,378 in revenue for the nine mon
• $30,378 — and 2023, respectively, and $11,755 and $30,378 in revenue for the nine months ended Se

Filing Documents

• cdio_s1.htm (S-1) — 2243KB
• ex5x1.htm (EX-5.1) — 11KB
• ex23x1.htm (EX-23.1) — 2KB
• ex107.htm (EX-FILING FEES) — 13KB
• image_002.jpg (GRAPHIC) — 3KB
• image_003.jpg (GRAPHIC) — 3KB
• image_004.jpg (GRAPHIC) — 16KB
• image_005.jpg (GRAPHIC) — 36KB
• image_006.jpg (GRAPHIC) — 35KB
• image_007.jpg (GRAPHIC) — 40KB
• image_008.jpg (GRAPHIC) — 30KB
• image_009.jpg (GRAPHIC) — 39KB
• shartis.jpg (GRAPHIC) — 15KB
• 0001079973-24-001610.txt ( ) — 8623KB
• cdio-20240930.xsd (EX-101.SCH) — 55KB
• cdio-20240930_cal.xml (EX-101.CAL) — 60KB
• cdio-20240930_def.xml (EX-101.DEF) — 208KB
• cdio-20240930_lab.xml (EX-101.LAB) — 403KB
• cdio-20240930_pre.xml (EX-101.PRE) — 341KB
• cdio_s1_htm.xml (XML) — 1179KB

USE OF PROCEEDS

USE OF PROCEEDS 43 DETERMINATION OF OFFERING PRICE 43 MARKET, PRICE, TICKER SYMBOLS AND DIVIDEND INFORMATION 43

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 44

BUSINESS

BUSINESS 55 MANAGEMENT 84 EXECUTIVE AND DIRECTOR COMPENSATION 92 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 98 PRINCIPAL STOCKHOLDERS 101 SELLING STOCKHOLDERS 103

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 105 PLAN OF DISTRIBUTION 111 CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS 114 LEGAL MATTERS 120 EXPERTS 120 WHERE YOU CAN FIND MORE INFORMATION 120 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information provided in this prospectus, as well as the information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling stockholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus, any applicable prospectus supplement or any documents incorporated by reference is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the selling stockholders may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the sale by such selling stockholders of the securities offered by it described in this prospectus. Neither we nor the selling stockholders have authorized anyone to provide any information or to make any representations other than those contained in this prospectus and any accompanying prospectus supplement. We and the selling stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offer

View Full Filing

View this S-1 filing on SEC EDGAR